IRIS
BAROCELLI, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.223
AS - Asia 10.691
EU - Europa 10.588
SA - Sud America 1.711
AF - Africa 594
Continente sconosciuto - Info sul continente non disponibili 34
OC - Oceania 8
Totale 42.849
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.787
SG - Singapore 4.178
CN - Cina 3.862
FI - Finlandia 1.991
SE - Svezia 1.752
IE - Irlanda 1.650
BR - Brasile 1.384
IT - Italia 1.322
DE - Germania 1.200
UA - Ucraina 964
HK - Hong Kong 837
VN - Vietnam 635
TR - Turchia 454
NL - Olanda 388
GB - Regno Unito 381
ZA - Sudafrica 359
CA - Canada 286
IN - India 229
RU - Federazione Russa 195
FR - Francia 184
AR - Argentina 130
BE - Belgio 127
CI - Costa d'Avorio 119
AT - Austria 95
BD - Bangladesh 95
MX - Messico 87
JP - Giappone 68
CZ - Repubblica Ceca 60
PL - Polonia 59
ID - Indonesia 58
RO - Romania 58
EC - Ecuador 54
IQ - Iraq 54
ES - Italia 51
KR - Corea 40
PK - Pakistan 33
CO - Colombia 32
EU - Europa 32
PY - Paraguay 30
LT - Lituania 28
VE - Venezuela 28
CM - Camerun 26
MA - Marocco 24
AZ - Azerbaigian 16
CL - Cile 16
PA - Panama 16
PE - Perù 15
UZ - Uzbekistan 15
EG - Egitto 14
KE - Kenya 14
JO - Giordania 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
BG - Bulgaria 11
IR - Iran 11
CR - Costa Rica 10
MY - Malesia 10
NP - Nepal 10
BO - Bolivia 9
CH - Svizzera 9
UY - Uruguay 9
SA - Arabia Saudita 8
TW - Taiwan 8
AL - Albania 7
DO - Repubblica Dominicana 7
HU - Ungheria 7
AU - Australia 6
BY - Bielorussia 6
DZ - Algeria 6
IL - Israele 6
JM - Giamaica 6
SC - Seychelles 6
DK - Danimarca 5
EE - Estonia 5
HN - Honduras 5
KZ - Kazakistan 5
OM - Oman 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
HR - Croazia 4
LB - Libano 4
LU - Lussemburgo 4
PT - Portogallo 4
RS - Serbia 4
SN - Senegal 4
TH - Thailandia 4
BH - Bahrain 3
BN - Brunei Darussalam 3
MD - Moldavia 3
NG - Nigeria 3
NI - Nicaragua 3
PH - Filippine 3
QA - Qatar 3
SV - El Salvador 3
AM - Armenia 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
GY - Guiana 2
Totale 42.820
Salva come PNG Salva come JPEG
Città #
Dallas 5.839
Singapore 2.155
Chandler 1.661
Dublin 1.649
Ashburn 1.478
Jacksonville 1.112
Santa Clara 1.011
Beijing 976
Ann Arbor 894
Hong Kong 828
Dearborn 768
Boardman 534
Parma 462
Nanjing 426
Izmir 396
New York 344
Johannesburg 342
Princeton 310
Shanghai 304
Munich 292
Los Angeles 262
Ho Chi Minh City 261
Wilmington 213
San Mateo 210
Hefei 189
Toronto 178
Helsinki 173
Bremen 151
Hebei 133
Kunming 133
São Paulo 133
Nanchang 132
Shenyang 126
Brussels 123
Jinan 121
Hanoi 120
Abidjan 119
Buffalo 108
Moscow 108
Des Moines 96
Guangzhou 89
Columbus 88
Grafing 84
Woodbridge 83
Vienna 82
Tianjin 80
Turku 73
Seattle 69
Changsha 64
Chicago 64
Tokyo 64
Jiaxing 63
London 58
Fremont 53
Brooklyn 52
Rio de Janeiro 52
Council Bluffs 47
Frankfurt am Main 47
Houston 46
Bologna 44
Warsaw 43
Hangzhou 41
Milan 41
Montreal 41
The Dalles 41
Norwalk 40
Zhengzhou 37
Chennai 35
Jakarta 35
San Jose 35
Phoenix 34
Amsterdam 33
Auburn Hills 33
Ottawa 32
Belo Horizonte 31
Nuremberg 31
Pune 31
Brno 30
Poplar 30
Stockholm 30
Haiphong 29
Marseille 29
Orem 29
Boston 28
Denver 28
Redondo Beach 28
Bangalore 27
West Jordan 27
Atlanta 26
Seoul 26
Brasília 25
Düsseldorf 25
Haikou 25
Manchester 24
San Francisco 24
Curitiba 23
Kocaeli 23
Modena 23
Fuzhou 22
Mexico City 21
Totale 27.388
Salva come PNG Salva come JPEG
Nome #
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.639
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.636
1,4-dioxane, a suitable scaffold for the development of novel M3 muscarinic receptor antagonists 1.589
1,5-Benzodiazepin tricyclic derivatives as analgersic, anti-inflammatory and /or antipyretic agents with very low acute gastrolesivity and toxicity 1.576
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 229
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 222
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 215
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 210
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 208
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 201
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 197
2-Aminobenzimidazoles as new potent H3-antagonists 196
3D-printed chitosan-based scaffolds: An in vitro study of human skin cell growth and an in-vivo wound healing evaluation in experimental diabetes in rats 187
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 186
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 181
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model 181
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 180
Bifidobacterium bifidum PRL2010 alleviates intestinal ischemia/reperfusioni injury 180
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 174
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation 174
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 171
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 171
Comparison of the effects of structurally different H2-antagonists on acid and pepsin activity stimulated by dimaprit in conscious cats 170
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 170
Aminobenzimidazoles as new potent H3-antagonists 169
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 168
Protective Effects of a Protease Inhibitor (Gabexate Mesilate) on Intestinal Ischemia/Reperfusion Injury in Rats 164
Antinociceptive and gastroprotective effects of inhaled and orally administered Lavandula hybrida Reverchon “Grosso” essential oil 164
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 164
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 162
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 161
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 161
Caratterizzazione farmacologica in vitro di nuovi agonisti muscarinici analoghi dell'Oxotremorina 160
[Experimental tracheal transplantation. Literature review and proposal of an original surgical technique]. 160
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 159
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 158
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 158
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 157
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 157
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 157
A promising imidazole-free histamine H3 receptor antagonist with good brain penetration and anticholinesterase activity. 157
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 156
Azionifarmacologiche di composti alchilaminoalchilfenilbenzisotiazolici sul trattogastrointestinale 155
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 155
Daily assumption of fermented milk containing Bifidobacterium breve 246 B® promotes prophylactic effects against intestinal inflammation in mice 154
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 153
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 151
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 151
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 151
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 150
Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice 150
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 150
Adaptive changes in rat ileum motility induced by mild mesenteric ischemia/reperfusion injury: role of endogenous mediators and reperfusion time 149
Novel Analgesic Agents Obtained by Molecular Hybridization of Orthosteric and Allosteric Ligands 149
The anti-H1-histaminic and antimuscarinic effect of 2- and 4-[benzyl-(2-dimethylaminoethyl)amino]pyrimidine compounds]. 148
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 148
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 147
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 147
Gastrointestinal symptoms and local oxidative stress in a model of Parkinson's Disease in rats 147
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 147
Inflammatory proteases released in a mouse model of intestinal ischemia 146
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 146
Dual role of endogenous serotonin in 2,4,6-Trinitrobenzene Sulfonic Acid-induced colitis 145
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 144
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 143
Hake fish bone as a calcium source for efficient bone mineralization 143
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 142
Effect of μ Opioid Receptor Activation On Intestinal Ischemia/Reperfusion Injury in Mice 141
Biochemical platform for the identification of adverse effects triggered by free hemoglobin in guinea pigs 141
A preliminary study of engineered nanoparticles effects on barrier function of airway epithelial monolayers 141
Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum 141
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 140
4-(3-Oxo-1,2-benzisothiazolin-2-yl)alkanoic, phenyl and phenoxyalkanoic acids: synthesis and anti-inflammatory, analgesic, and antipyretic properties 140
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 140
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 140
Regional differences in motor responsiveness to antimuscarinic drugs in rabbit isolated small and large intestine 139
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 139
Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers 139
Antinociceptive affects of inhalated and orally administered Lavandula hybrida Reverchon "Grosso" essential oil 138
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 137
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 136
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 136
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 136
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 136
Analgesici-antipiretici benzopirano pirimidinici non acidici attivi per via orale privi di gastrolesività 136
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae. 135
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 133
Nuovi potenti agonisti muscarinici oxotremorina-M simili a struttura acetilenica: studio funzionale in vitro 133
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 133
Analgesic activity of new hybrid muscarinic agonists in mice 132
5-HT1A receptors as target to protect the intestine in an experimental model of colitis 131
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 131
Rifaximin anti-inflammatory activity on bovine endometrium primary cell cultures: a preliminary study 131
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 131
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 131
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 130
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 130
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 130
Motor responses of rat hypertrophic intestine following chronic obstruction 130
Effects of antimuscarinic agents, H2-blockers and omeprazole on rat chronic gastric ulcer after long-a and short-term administration 128
Totale 21.311
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.571
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.571
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.406 0 0 0 0 0 109 279 50 458 96 336 78
2021/20221.869 64 57 53 239 117 126 199 213 71 125 116 489
2022/20236.474 760 675 390 473 646 725 111 361 1.997 57 199 80
2023/20242.213 128 194 59 88 168 565 211 119 85 111 160 325
2024/20257.401 229 397 514 411 723 870 281 353 817 690 628 1.488
2025/202614.253 1.559 2.604 5.657 1.642 2.238 553 0 0 0 0 0 0
Totale 43.179